Omontys approved for anemic people with kidney disease

March 27, 2012

(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.

Anemia is characterized by a lack of enough healthy . The newly approved drug is designed to stimulate bone marrow to produce more of these cells, reducing a person's need for a blood transfusion, the FDA said Tuesday in a news release.

Clinical testing of the once-monthly injection involved 1,608 people with abnormally low hemoglobin, a measure of anemia. The most common side effects were diarrhea, vomiting, high blood pressure and pain in the joints, back, legs or arms, the agency said.

Omontys should not be used in people with who are not on dialysis, nor those with cancer-related anemia, the FDA warned. It should also not be used as a substitute in people who require an immediate to treat anemia.

Omontys is marketed by Palo Alto, Calif.-based Affymax Inc.

Explore further: Fixing common blood disorder would make kidney transplants more successful

More information: The U.S. National Library of Medicine has more about anemia.

Related Stories

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.